ALT5 Sigma Corporation Added to the Russell Microcap Growth Index, Russell 3000E Index and Russell 3000E Growth Index
ALT5 Sigma Corporation (NASDAQ:ALTS) has announced its addition to three Russell indexes: the Russell Microcap Growth®, Russell 3000E®, and Russell 3000E Growth® Indexes as part of the 2025 Russell indexes reconstitution. The company had previously been included in the Russell Microcap® Index since June 2024.
ALT5 Sigma, founded in 2018, is a fintech company providing blockchain-powered payment and trading infrastructure. The company has processed over $5 billion USD in cryptocurrency transactions since inception and supports over 1,000 businesses globally through its two main platforms: ALT5 Pay and ALT5 Prime.
Additionally, the company is advancing the separation of its biotech business under "Alyea Therapeutics Corporation," which is developing JAN123, a novel low-dose naltrexone formulation for Complex Regional Pain Syndrome (CRPS) that has received FDA Orphan Drug Designation.
ALT5 Sigma Corporation (NASDAQ:ALTS) è stata inclusa in tre indici Russell: Russell Microcap Growth®, Russell 3000E® e Russell 3000E Growth®, nell’ambito della ristrutturazione degli indici Russell 2025. In precedenza, la società era già presente nell’indice Russell Microcap® dal giugno 2024.
Fondata nel 2018, ALT5 Sigma è una fintech che offre infrastrutture di pagamento e trading basate su blockchain. Da allora ha elaborato oltre 5 miliardi di dollari in transazioni in criptovalute e supporta più di 1.000 aziende a livello globale attraverso le sue due piattaforme principali: ALT5 Pay e ALT5 Prime.
Inoltre, la società sta portando avanti la separazione della sua divisione biotech sotto il nome di "Alyea Therapeutics Corporation", che sta sviluppando JAN123, una nuova formulazione a basso dosaggio di naltrexone per la Sindrome da Dolore Regionale Complesso (CRPS), che ha ottenuto la Designazione di Farmaco Orfano dalla FDA.
ALT5 Sigma Corporation (NASDAQ:ALTS) ha anunciado su inclusión en tres índices Russell: Russell Microcap Growth®, Russell 3000E® y Russell 3000E Growth®, como parte de la reconstitución de los índices Russell 2025. La compañía ya formaba parte del índice Russell Microcap® desde junio de 2024.
Fundada en 2018, ALT5 Sigma es una fintech que proporciona infraestructura de pagos y comercio basada en blockchain. Desde su creación, ha procesado más de 5 mil millones de dólares en transacciones de criptomonedas y apoya a más de 1,000 empresas a nivel mundial a través de sus dos plataformas principales: ALT5 Pay y ALT5 Prime.
Además, la compañía está avanzando en la separación de su negocio biotecnológico bajo el nombre "Alyea Therapeutics Corporation", que desarrolla JAN123, una nueva formulación de naltrexona en dosis bajas para el Síndrome de Dolor Regional Complejo (CRPS) que ha recibido la Designación de Medicamento Huérfano por la FDA.
ALT5 Sigma Corporation (NASDAQ:ALTS)는 2025년 러셀 지수 재구성의 일환으로 Russell Microcap Growth®, Russell 3000E®, Russell 3000E Growth® 등 세 가지 러셀 지수에 추가되었다고 발표했습니다. 이 회사는 2024년 6월부터 Russell Microcap® 지수에 포함되어 있었습니다.
2018년에 설립된 ALT5 Sigma는 블록체인 기반 결제 및 거래 인프라를 제공하는 핀테크 기업입니다. 설립 이후 50억 달러 이상의 암호화폐 거래를 처리했으며, 두 주요 플랫폼인 ALT5 Pay와 ALT5 Prime을 통해 전 세계 1,000개 이상의 기업을 지원하고 있습니다.
또한, 회사는 "Alyea Therapeutics Corporation"이라는 이름으로 바이오텍 사업 분리를 추진 중이며, FDA 희귀의약품 지정을 받은 복합부위통증증후군(CRPS) 치료를 위한 저용량 날트렉손 신약 제형 JAN123을 개발하고 있습니다.
ALT5 Sigma Corporation (NASDAQ:ALTS) a annoncé son inclusion dans trois indices Russell : Russell Microcap Growth®, Russell 3000E® et Russell 3000E Growth®, dans le cadre de la reconstitution des indices Russell 2025. La société était déjà présente dans l’indice Russell Microcap® depuis juin 2024.
Fondée en 2018, ALT5 Sigma est une fintech fournissant une infrastructure de paiement et de trading basée sur la blockchain. Depuis sa création, elle a traité plus de 5 milliards de dollars de transactions en cryptomonnaies et soutient plus de 1 000 entreprises dans le monde via ses deux principales plateformes : ALT5 Pay et ALT5 Prime.
Par ailleurs, la société fait progresser la scission de son activité biotechnologique sous le nom « Alyea Therapeutics Corporation », qui développe JAN123, une nouvelle formulation à faible dose de naltrexone pour le syndrome douloureux régional complexe (CRPS), ayant reçu la désignation de médicament orphelin par la FDA.
ALT5 Sigma Corporation (NASDAQ:ALTS) wurde im Rahmen der Russell-Index-Neuzusammensetzung 2025 in drei Russell-Indizes aufgenommen: Russell Microcap Growth®, Russell 3000E® und Russell 3000E Growth®. Das Unternehmen war bereits seit Juni 2024 im Russell Microcap® Index vertreten.
ALT5 Sigma, gegründet 2018, ist ein Fintech-Unternehmen, das blockchain-basierte Zahlungs- und Handelsinfrastruktur anbietet. Seit seiner Gründung hat das Unternehmen über 5 Milliarden US-Dollar an Kryptowährungstransaktionen abgewickelt und unterstützt mehr als 1.000 Unternehmen weltweit über seine beiden Hauptplattformen ALT5 Pay und ALT5 Prime.
Darüber hinaus treibt das Unternehmen die Ausgliederung seines Biotech-Geschäfts unter dem Namen "Alyea Therapeutics Corporation" voran, das JAN123 entwickelt, eine neuartige Niedrigdosis-Naltrexon-Formulierung zur Behandlung des Komplexen Regionalen Schmerzsyndroms (CRPS), die von der FDA den Status eines Orphan Drugs erhalten hat.
- Inclusion in multiple prestigious Russell indexes indicates growing market recognition
- Processed over $5 billion USD in cryptocurrency transactions since inception
- Serves over 1,000 businesses globally
- FDA Orphan Drug Designation received for JAN123 pain treatment
- Expanding business scope through biotech division separation
- None.
Insights
ALT5's addition to Russell 3000E indices marks significant milestone, boosting visibility and potential institutional interest for the blockchain payment provider.
ALT5 Sigma's inclusion in the Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth indices represents a significant milestone in the company's market recognition. This advancement from its previous position solely in the Russell Microcap Index indicates the company has crossed important market capitalization thresholds, as Russell indices are strictly constructed based on objective market cap rankings and style attributes.
The Russell 3000E index serves as a broader benchmark that encompasses approximately 99% of the investable US equity market, making this inclusion particularly noteworthy for ALT5. For context, the Russell indices collectively serve as benchmarks for approximately
This index inclusion carries tangible benefits beyond mere prestige. It automatically places ALT5 into the investment universe of passive funds tracking these indices, potentially creating buying pressure. More importantly, it significantly enhances visibility among institutional investors who use these benchmarks to evaluate investment opportunities.
The operational metrics disclosed further contextualize this achievement: processing over
The timing of this announcement coincides with FTSE Russell's move toward semi-annual reconstitution starting in 2026, indicating ALT5 has secured its position during a particularly significant recalibration period for these indices.
LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) ("ALT5 or the "Company"), a fintech company providing blockchain-powered payment and trading infrastructure for global merchants and financial institutions, has announced today that it has been added as a member of the Russell Microcap Growth®, Russell 3000E® and Russell 3000E Growth® Indexes, as part of the 2025 Russell indexes reconstitution. The Company had previously been included in the Russel Microcap® Index since June of 2024.
"The recent reconstitution of the Russell indexes and our inclusion in both the Russell 3000E and Russell 3000E Growth Indexes is a powerful validation of our sustained momentum and strengthening fundamentals," said Peter Tassiopoulos, CEO of ALT5 Sigma Corporation. "This recognition reflects the market's growing confidence in our strategic vision, execution capabilities, and long-term value creation for stockholders. We are honored to be part of these prestigious benchmarks and see it as a catalyst for increased visibility and institutional interest moving forward."
FTSE Russell determines index membership primarily based on objective market capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. As of June 28, 2024, Russell's U.S. indexes served as the benchmark for approximately
Peter Tassiopoulos went on to comment "Today's announcement builds on ALT5's position as a leading provider of blockchain-based payment and trading infrastructure. Founded in 2018, the Company supports over 1,000 businesses globally and has processed more than
Fiona Bassett, CEO of FTSE Russell, An LSEG business, comments:
"The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark."
For more information on the Russell Microcap® Index and the Russell indexes reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website.
About ALT5 Sigma Corporation
ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. the Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: "ALT5 Pay" and "ALT5 Prime." The company has processed over
ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.
The Company is also advancing the separation of its biotech business, which will continue under "Alyea Therapeutics Corporation." Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell.
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.
Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Media/Investor Relations Contact
IR@alt5sigma.com
1-800-400-2247
SOURCE: ALT5 Sigma Corp
View the original press release on ACCESS Newswire
FAQ
What Russell indexes was ALT5 Sigma (ALTS) added to in 2025?
How much in cryptocurrency transactions has ALT5 Sigma (ALTS) processed?
What are the main platforms offered by ALT5 Sigma (ALTS)?
What is ALT5 Sigma's (ALTS) biotech division developing?
How many businesses does ALT5 Sigma (ALTS) support globally?
